Celgene to pay Mylan $62 Million to Resolve Cancer Drug Antitrust Case

Celgene to pay Mylan $62 Million to Resolve Cancer Drug Antitrust Case

Aug 02, 2019PR-M08-19-NI-007

Reuters - Mylan NV says Celgene Corp will pay it $62 million to resolve a lawsuit alleging the drugmaker improperly stifled competition for its cancer treatment drugs Thalomid and Revlimid by preventing generic versions from entering the market.

Mylan disclosed the settlement in a filing with the U.S. Securities and Exchange Commission on Monday, days after Celgene agreed to pay $55 million to resolve a related class action lawsuit in federal court in Newark, New Jersey.